×

Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

Biomea Fusion Inc. (BMEA) NASDAQ

$15.36 0.41 (2.74%)

Market Cap: $548.44M

As of 03/27/24 04:00 PM EDT. Market closed.

(BMEA)

Biomea Fusion Inc. (BMEA)
NASDAQ

$15.36
0.41 (2.74%)

Market Cap: $548.44M

As of 03/27/24 04:00 PM EDT. Market closed.

Add to Portfolio

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a ... read more

biomea fusion, llc was formed in 2017 by a small group of biotech executives. we are dedicated to developing innovative medicines for patients. it is our goal to design and clinically develop patient friendly therapies with higher efficacy than the current standard of care. the more precise a therapeutic agent is, the better the potential outcomes for individual patients’ needs. we are a precision oncology company developing novel small molecules that target aggressive forms of cancer. patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. with our current program, we are targeting specific changes to the dna of patients, which can be isolated as key drivers for tumor growth. we leverage our internal expertise and compliment it with computational drug design technology to build novel medicines for the future. we have significantly invested in the upfront development of our targeted therapies and are conducting bro read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
URL
Address
.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Full Time Employees
76
Address
.
PRICE CHART FOR BIOMEA FUSION INC
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
INSIDEARBITRAGE ARTICLES
KEY STATS
Open
$15.40
Previous Close
$14.95
Days Range
$14.70 - $15.56
52 week range
$8.13 - $43.69
Volume
713,757
Avg. Volume (30 days)
1,330,118
Market Cap
$548.44M
Dividend Yield
-
P/E
-
Shares Outstanding
35,705,786
Open
$15.40
Previous Close
$14.95
Days Range
$14.70 - $15.56
52 week range
$8.13 - $43.69
Volume
713,757
Avg. Volume (30 days)
1,330,118
Market Cap
$548.44M
Dividend Yield
-
P/E
-
Shares Outstanding
35,705,786
FINANCIAL STATEMENTS FOR BIOMEA FUSION INC
LOADING...

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR BIOMEA FUSION INC
OwnerRelationshipDateTransactionCost# SharesValue($)Total SharesForm 4
Valle FrancoChief Financial OfficerNov 30, 2023 Option Exercise$3.781,3455,08725,543Dec 01, 2023, 05:58 PM
Valle FrancoChief Financial OfficerMay 31, 2023 Option Exercise$3.784,27316,16324,198Jun 02, 2023, 05:01 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 31, 2023 Sale$33.8175,0002,535,7503,550,000Jun 02, 2023, 05:00 PM
A2A Pharmaceuticals, Inc.10% OwnerJun 01, 2023 Sale$34.5650,0001,728,1653,500,000Jun 02, 2023, 05:00 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 12, 2023 Sale$33.8425,000846,0003,625,000May 17, 2023, 07:13 AM
A2A Pharmaceuticals, Inc.10% OwnerMay 09, 2023 Sale$34.50150,0005,175,7203,650,000May 10, 2023, 05:19 PM
A2A Pharmaceuticals, Inc.10% OwnerMay 08, 2023 Sale$33.99100,0003,399,3103,800,000May 10, 2023, 05:19 PM
A2A Pharmaceuticals, Inc.10% OwnerApr 20, 2023 Sale$29.12200,0005,823,7603,900,000Apr 26, 2023, 08:36 AM
A2A Pharmaceuticals, Inc.10% OwnerMar 31, 2023 Sale$31.25200,0006,250,0004,100,000Apr 06, 2023, 07:31 PM
A2A Pharmaceuticals, Inc.10% OwnerMar 31, 2023 Sale$31.25200,0006,250,0004,100,000Apr 06, 2023, 06:43 PM
Chen BihuaDirectorMar 30, 2023 Buy$30.00400,00012,000,0003,570,872Apr 03, 2023, 04:30 PM
Erdtmann Rainer MPresident and COOApr 15, 2021 Buy$17.003,00051,0003,000Feb 10, 2023, 04:10 PM
Erdtmann Rainer MPresident and COOApr 15, 2021 Buy$17.005,40091,8003,000Feb 10, 2023, 04:10 PM
Valle FrancoChief Financial OfficerNov 30, 2022 Option Exercise$3.782,5189,52419,925Dec 02, 2022, 04:30 PM
Hitchcock Michael J.M.DirectorNov 14, 2022 Buy$7.935,00039,6505,000Nov 16, 2022, 04:30 PM
Valle FrancoChief Financial OfficerNov 11, 2022 Buy$7.634,10031,28617,407Nov 14, 2022, 04:30 PM
A2A Pharmaceuticals, Inc.10% OwnerAug 16, 2022 Buy$13.8730,684425,6484,300,000Aug 19, 2022, 06:56 AM
A2A Pharmaceuticals, Inc.10% OwnerJul 21, 2022 Sale$11.2134,658388,5164,330,684Jul 25, 2022, 07:16 PM
A2A Pharmaceuticals, Inc.10% OwnerJun 24, 2022 Sale$11.7634,658407,5784,365,342Jun 28, 2022, 07:51 AM
Valle FrancoChief Financial OfficerMay 31, 2022 Option Exercise$4.673,30715,43213,307Jun 01, 2022, 06:00 PM
Valle FrancoChief Financial OfficerJan 14, 2022 Buy$8.6810,00086,76710,000Jan 18, 2022, 07:00 PM
A2A Pharmaceuticals, Inc.10% OwnerSep 17, 2021 Buy$10.9634,658379,8524,400,000Sep 21, 2021, 04:05 PM
Stergiopoulos SotiriosDirectorSep 17, 2021 Buy$10.9634,658379,8524,400,000Sep 21, 2021, 04:05 PM
Erdtmann Rainer MPresident & COOAug 23, 2021 Buy$13.2024,000316,872228,470Aug 25, 2021, 08:56 PM
Butler Thomas AndrewCEOAug 23, 2021 Buy$13.2024,000316,872228,470Aug 25, 2021, 08:55 PM
Erdtmann Rainer MPresident & COOAug 18, 2021 Buy$10.7714,000150,738204,470Aug 19, 2021, 09:41 PM
Erdtmann Rainer MPresident & COOAug 17, 2021 Buy$10.7914,000151,067190,470Aug 19, 2021, 09:41 PM
Erdtmann Rainer MPresident & COOApr 15, 2021 Buy$17.00176,4702,999,990176,470Aug 19, 2021, 09:41 PM
Butler Thomas AndrewCEOAug 18, 2021 Buy$10.7714,000150,738204,470Aug 19, 2021, 09:40 PM
Butler Thomas AndrewCEOAug 17, 2021 Buy$10.7914,000151,067190,470Aug 19, 2021, 09:40 PM
Butler Thomas AndrewCEOApr 15, 2021 Buy$17.00176,4702,999,990176,470Aug 19, 2021, 09:40 PM
Chen BihuaDirectorApr 20, 2021 Buy$17.00900,00015,300,0003,170,872Apr 22, 2021, 04:09 PM
Load More Insider Transactions
Buy Sale Option Exercise
OwnerRelationshipDateValue($)
Valle FrancoChief Financial Officer11/30/20235,087
Valle FrancoChief Financial Officer05/31/202316,163
A2A Pharmaceuticals, Inc.10% Owner05/31/20232,535,750
A2A Pharmaceuticals, Inc.10% Owner06/01/20231,728,165
A2A Pharmaceuticals, Inc.10% Owner05/12/2023846,000
A2A Pharmaceuticals, Inc.10% Owner05/09/20235,175,720
A2A Pharmaceuticals, Inc.10% Owner05/08/20233,399,310
A2A Pharmaceuticals, Inc.10% Owner04/20/20235,823,760
A2A Pharmaceuticals, Inc.10% Owner03/31/20236,250,000
A2A Pharmaceuticals, Inc.10% Owner03/31/20236,250,000
Chen BihuaDirector03/30/202312,000,000
Erdtmann Rainer MPresident and COO04/15/202151,000
Erdtmann Rainer MPresident and COO04/15/202191,800
Valle FrancoChief Financial Officer11/30/20229,524
Hitchcock Michael J.M.Director11/14/202239,650
Valle FrancoChief Financial Officer11/11/202231,286
A2A Pharmaceuticals, Inc.10% Owner08/16/2022425,648
A2A Pharmaceuticals, Inc.10% Owner07/21/2022388,516
A2A Pharmaceuticals, Inc.10% Owner06/24/2022407,578
Valle FrancoChief Financial Officer05/31/202215,432
Valle FrancoChief Financial Officer01/14/202286,767
A2A Pharmaceuticals, Inc.10% Owner09/17/2021379,852
Stergiopoulos SotiriosDirector09/17/2021379,852
Erdtmann Rainer MPresident & COO08/23/2021316,872
Butler Thomas AndrewCEO08/23/2021316,872
Erdtmann Rainer MPresident & COO08/18/2021150,738
Erdtmann Rainer MPresident & COO08/17/2021151,067
Erdtmann Rainer MPresident & COO04/15/20212,999,990
Butler Thomas AndrewCEO08/18/2021150,738
Butler Thomas AndrewCEO08/17/2021151,067
Butler Thomas AndrewCEO04/15/20212,999,990
Chen BihuaDirector04/20/202115,300,000
Load More Insider Transactions
FUNDS WITH A POSITION IN BIOMEA FUSION INC
Fund# Shares Owned% of Portfolio% ChangeInvesting Style
BLACKROCK INC.2,156,3420.0008%4.26%Other
BAKER BROS. ADVISORS LP2,108,9490.35%No changeOther
DRIEHAUS CAPITAL MANAGEMENT LLC1,182,7410.21%29.56%Growth
GEODE CAPITAL MANAGEMENT, LLC480,3220.00073%5.97%Other
ADAGE CAPITAL PARTNERS GP, L.L.C.180,0000.00562%ExitedOther
D. E. SHAW & CO., INC.52,9940.00067%NewOther
ALPS ADVISORS INC30,3990.00347%NewOther
BALYASNY ASSET MANAGEMENT L.P.22,4280.00061%NewEvent Driven
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)11,2060.003%NewOther
AQR CAPITAL MANAGEMENT LLC10,6220.0003%ExitedOther
CHANGE IN SHARES OUTSTANDING FOR BIOMEA FUSION INC
STOCK BUYBACKS FOR BIOMEA FUSION INC
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
09/30/2023
06/30/2023
0.86%
1Q
09/30/2023
03/31/2023
20.51%
2Q
09/30/2023
12/31/2022
21.09%
3Q
09/30/2023
09/30/2022
21.61%
4Q
09/30/2023
06/30/2022
22.12%
5Q
09/30/2023
03/31/2022
22.41%
6Q
09/30/2023
12/31/2021
49.44%
7Q
09/30/2023
09/30/2021
22.94%
8Q
09/30/2023
06/30/2021
41.70%
9Q
Load More

Period of Report: 09/30/2023

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
06/30/2023
0.86%
1Q
03/31/2023
20.51%
2Q
12/31/2022
21.09%
3Q
09/30/2022
21.61%
4Q
06/30/2022
22.12%
5Q
03/31/2022
22.41%
6Q
12/31/2021
49.44%
7Q
09/30/2021
22.94%
8Q
06/30/2021
41.70%
9Q
Load More
BUYBACK ANNOUNCEMENT(S) FOR BIOMEA FUSION INC
LOADING...